Could #menin be the key to understanding the development of NPM1-m and KMT2A-r #AML? While menin is known for its multiple functions, it plays a crucial role in regulating gene expression. Emerging research indicates that activation of the menin pathway may significantly impact the development of NPM1-m and KMT2A-r AML, unlocking new insights into the complexities of AML. Kura Oncology is investigating the potential of menin inhibition with #ziftomenib in patients with AML. See ongoing clinical trials: https://bit.ly/3A2vZL1
Kura Oncology, Inc.
Biotechnology Research
San Diego, California 21,517 followers
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
About us
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
- Website
-
http://www.kuraoncology.com
External link for Kura Oncology, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2014
- Specialties
- Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
Locations
-
Primary
12730 High Bluff Dr
Suite 400
San Diego, California 92130, US
-
2 Seaport Ln
Suite 8A
Boston, Massachusetts 02210, US
Employees at Kura Oncology, Inc.
Updates
-
At #FierceJPM Week, CEO Troy Wilson, Ph.D., J.D. gave his insights on the Inflation Reduction Act (#IRA), including how we can move forward in the best interest of patients. Hear more in the clip below and view more highlights from the panel here: https://lnkd.in/g8FgCRCD
-
Congratulations to our very own Chief Operating Officer Kathy Ford for being named in the 2024 PharmaVoice 100 list! This prestigious award recognizes the top 100 influential industry leaders who are devoted to lifting the pillars of #biotech and drug development to new heights. Join us in congratulating Kathy on her accomplishment! See the full list here: https://bit.ly/4gQi6Ah
-
This #HispanicHeritageMonth, we reflect on the remarkable contributions of Hispanic leaders in #biotech and beyond. At Kura, we are proud of the diverse talent that fuels our success. Hear more from #TeamKura member Alma Ortiz on our commitment to inclusivity. #HHM24
-
#TeamKura is proud to join the The Leukemia & Lymphoma Society for our 4th consecutive #LighttheNight event! Together, we're bringing light to the darkness of cancer by supporting groundbreaking research and bringing hope to patients and families battling blood cancers. Join us as we walk to celebrate, honor, and remember those affected. Find a Light the Night walk near you and help shine a light in the fight against blood cancer! https://lnkd.in/dFqbRn8 #LLSUSA
-
At Kura, we believe in cultivating an environment where every voice is heard, nurtured, and valued. This #GlobalDiversityAwarenessMonth, we’re honored to highlight our ongoing partnership with Life Science Cares San Diego and Life Science Cares Boston. Through our mutual collaboration, we provide underrepresented students the tools and experiences to pursue a career in #STEM. By removing barriers and creating growth opportunities, we’re hoping to build a more diverse workforce that will drive the next wave of scientific breakthroughs. Thank you to Life Science Cares for your continued efforts to build equity and inclusion for all! #GlobalDiversityAwarenessMonth
-
Data from our KOMET-001 Phase 1 study has been published in The Lancet Oncology journal! Learn more about the clinical data and what it means for ziftomenib’s potential in relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (#AML): https://bit.ly/3XFaYO8
-
On #RareCancerDay, September 30, join Kura Oncology in showing support for patients, clinicians, and scientists fighting rare cancers. Despite >500 types of rare cancers, fewer than 40,000 people are affected annually. With fewer patients, rare cancers can be hard to study, treat, and cure. Through its ongoing clinical trial programs, Kura Oncology is exploring new therapies designed to address rare cancer challenges. Learn about our clinical trial programs in head and neck cancer, lung cancer, and acute leukemias: https://bit.ly/4earkWd
-
Our Chief Commercial Officer, Brian Powl, will join a panel discussion around best practices for effective drug launch planning at the 2024 Fierce New Product Planning Summit in Boston next week. Here, he will share his insights from his experience across pharma and biotechnology companies. Learn more: https://sched.co/1ehzT Fierce Life Sciences Events | #FierceNPP
-
For the second year in a row, we are #ScripAwards finalists! Thank you to our partners and everyone at #TeamKura for your work in securing two finalist slots, including: Executive of the Year for our President and CEO, Troy Wilson, Ph.D., J.D. and Community Partnership of the Year for our ongoing collaboration with Life Science Cares San Diego and Life Science Cares Boston. See the full shortlist of Citeline’s 2024 Scrip Awards here and stay tuned as the winners are announced.: https://bit.ly/3Bb1mDz